soul trial oral semaglutide cardiovascular outcomes soul trial results Subcutaneous demonstrated benefit in T2DM back in 2016 (SUSTAIN-6) with 26% MACE reduction. semaglutide demonstrates cardiovascular risk reduction in T2DM and high… SOUL trial shows oral semaglutide

After the FDA resolved the shortages, compounded GLP-1s are no longer available simply because they are cheaper

Additionally, our extensive lineup, including pioneering oral medications like Wegovy pill and Foundayo, offers unmatched flexibility

In Phase 2 cross-trial comparisons, retatrutide produced greater mean weight loss (~24% at 48 weeks) than published tirzepatide data (~2022% at 72 weeks)

As a result, certain dynamic metabolic shifts may not be fully captured, as with the 2D cell line screen

45 Selectins can be divided into three families according to the cell type in which they were first characterized: the L-, E-, and P-selectins, of which the L-selectins are expressed in neutrophils